Modality
ADC
MOA
BCL-2i
Target
Tau
Pathway
Autophagy
ADPKD
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
Mar 2022
→ Sep 2029
Phase 2Current
NCT06123894
584 pts·ADPKD
2023-03→2028-08·Not yet recruiting
NCT03465709
2,268 pts·ADPKD
2022-03→2029-09·Terminated
2,852 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-08-262.4y awayPh3 Readout· ADPKD
2029-09-083.4y awayPh3 Readout· ADPKD
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Termina…
P2/3
Not yet…
Catalysts
Ph3 Readout
2028-08-26 · 2.4y away
ADPKD
Ph3 Readout
2029-09-08 · 3.4y away
ADPKD
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06123894 | Phase 2/3 | ADPKD | Not yet recr... | 584 | 6MWD |
| NCT03465709 | Phase 2/3 | ADPKD | Terminated | 2268 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |